Risk Factors for Mesh Exposure after Transvaginal Mesh Surgery

Ke Niu, Yong-Xian Lu, Wen-Jie Shen, Ying-Hui Zhang, Wen-Ying Wang
Department of Gynaecology and Obstetrics, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China

Abstract

Background: Mesh exposure after surgery continues to be a clinical challenge for urogynecological surgeons. The purpose of this study was to explore the risk factors for polypropylene (PP) mesh exposure after transvaginal mesh (TVM) surgery.

Methods: This study included 195 patients with advanced pelvic organ prolapse (POP), who underwent TVM from January 2004 to December 2012 at the First Affiliated Hospital of Chinese PLA General Hospital. Clinical data were evaluated including patient’s demography, TVM type, concomitant procedures, operation time, blood loss, postoperative morbidity, and mesh exposure. Mesh exposure was identified through postoperative vaginal examination. Statistical analysis was performed to identify risk factors for mesh exposure.

Results: Two-hundred and nine transvaginal PP meshes were placed, including 194 in the anterior wall and 15 in the posterior wall. Concomitant tension-free vaginal tape was performed in 61 cases. The mean follow-up time was 35.1 ± 23.6 months. PP mesh exposure was identified in 32 cases (16.4%), with 31 in the anterior wall and 1 in the posterior wall. Significant difference was found in operating time and concomitant procedures between exposed and nonexposed groups (F = 7.443, P = 0.007; F = 4.307, P = 0.039, respectively). Binary logistic regression revealed that the number of concomitant procedures and operation time were risk factors for mesh exposure (P = 0.001, P = 0.043).

Conclusion: Concomitant procedures and increased operating time increase the risk for postoperative mesh exposure in patients undergoing TVM surgery for POP.

Key words: High Risk; Polypropylene; Transvaginal Mesh

Introduction

Pelvic organ prolapse (POP) is a major healthcare problem in middle-aged and elderly women and is usually accompanied by pelvic floor dysfunction (PFD).1 The number of patients with these disorders has increased as life expectancy has increased. The treatment of POP continues to be a clinical challenge for urogynecological surgeons. The introduction of mesh repair in vaginal prolapse surgery showed possible advantageous results in early reports. However, pelvic floor structures progressively weaken in the elderly women, contributing to the high rate of recurrence. It has been reported that more than 30% of patients undergoing prolapse repair need reoperation.4 Recent announcements from the US Food and Drug Administration (FDA) describe increasing concern for complications after transvaginal mesh (TVM) surgery.5

The risk factors for mesh exposure have been explored for decades, but it remains unclear what leads to the mesh exposure and operation failure. We analyzed clinical data to identify possible risk factors for mesh exposure to reduce the TVM complication rate and to improve patients’ quality of life.

Methods

Research design and trial population

A retrospective study of patients undergoing TVM surgery between January 2004 and December 2012 was conducted in the Department of Obstetrics and Gynecology at the...
First Affiliated Hospital of Chinese PLA General Hospital. All procedures used Gynecare Gynemesh PS produced by Ethicon. The operative methods included Prosima anterior leaf fixation, Prolift anterior leaf fixation, small mesh fixation, Prosima posterior leaf fixation, Prolift total pelvic fixation, tension-free vaginal tape (TVT), and TVT-obturator. Clinical data were collected including age, menopause status, body mass index (BMI), gravidity and parity, stage of the POP, TVM types, concomitant procedures, operation time, blood loss, postoperative morbidity, and postoperative mesh exposure. Only patients with at least 3 months of follow-up time were included. The study was approved by the Institutional Review Board of First Affiliated Hospital of Chinese PLA General Hospital.

**Statistical analysis**
Quantitative data were expressed as mean ± standard deviation (minimum, maximum) while categorical data were expressed as absolute number and rate. Statistical analysis was performed to analyze the risk factors for mesh exposure using the SPSS 10.0 software (SPSS Inc., USA). Independent sample’s t-test was used for comparisons between the two groups while binary logistic regression was adopted to explore the risk factors for mesh exposure. A value of P < 0.05 was considered statistically significant.

**RESULTS**

**Patient characteristics**
Data from 218 patients who had received reconstruction pelvic surgery (RPS) due to PFD from January 2004 to December 2012 data were collected. A total of 195 (89.4%) subjects were enrolled and 150 (68.8%) subjects were followed up for more than 2 years. The median follow-up time was 35.1 ± 23.6 months (range: 2.0–104.0 months). The average age was 63.9 ± 11.2 years (43.0–89.0 years, mean age 65.0 years). The median duration of menopause was 14.8 ± 10.7 years (range: 0–35.0 years). The average gravidity was 3.6 ± 1.6 times (range: 1–11 times) and the average parity was 2.6 ± 1.5 times (range: 1–9 times).

Fifty-three patients had diabetes and 108 patients had hypertension. Seven patients had a history of pelvic resection the vaginal mucosa healed completely. No mesh exposure was found in 32 patients, whose age ranged from 43 to 81 years. Most of the patients with mesh exposure were between 60 and 70 years old. The mean exposure diameter was 0.6 ± 0.3 cm (range: 0.3–1.5 cm) [Table 1]. The main clinical symptom of mesh exposure was vaginal discharge. The management of vaginal mesh exposure included regular observation, local application of estrogen ointment and metronidazole suppositories, and removal of exposed mesh. Most cases gradually healed in half a year. No mesh exposure progression was detected. There were eight patients who were admitted for removal of exposed mesh and after mesh resection the vaginal mucosa healed completely.

**Surgery**
A total of 195 patients underwent transvaginal RPS with polypropylene (PP) mesh; 180 (92.3%) received anterior prolapse surgery, 1 (0.5%) received posterior prolapse surgery, and 14 (7.2%) received combined anterior and posterior prolapse surgery. A total of 209 transvaginal PP meshes were placed; 194 in the anterior wall and 15 in the posterior wall. Concomitantly, transvaginal hysterectomy was performed in 189 (96.9%) cases, high uterosacral ligament suspension in 176 (90.2%), sacrospinous ligament fixation in 5 (2.5%), posterior wall colporrhaphy in 130 (66.7%), perineal repair in 160 (82.1%), and TVT in 61 (31.3%). The mean operative time was 2.4 ± 1.1 h (range: 1.0–4.0 h). The mean blood loss was 172.4 ± 75.3 ml (90.0–300.0 ml). The mean body temperature in the first 3 days after the operation was 37.1 ± 0.3°C (range: 36.8–38.2°C). No perioperative complications were observed.

**Postoperative follow-up**
The average follow-up time was 35.1 ± 23.6 months (range: 2–104 months). A successful operation was defined as Stage 2 or less by POP quantification (POP-Q) examination. Two patients had recurrence 3 months after surgery. All other patients were found by POP-Q to be Stage 2 or less up to half a year after the surgery. The objective success rate was 98.9%, and no patient was reoperated because of recurrence.

Mesh exposure was defined by criteria established by the International Urogynecological Association and the International Continence Society[6] [Figure 1a and 1b]. Mesh exposure was found in 32 patients, whose age ranged from 43 to 81 years. Most of the patients with mesh exposure were between 60 and 70 years old. The mean exposure diameter was 0.6 ± 0.3 cm (range: 0.3–1.5 cm) [Table 1]. The main clinical symptom of mesh exposure was vaginal discharge. The management of vaginal mesh exposure included regular observation, local application of estrogen ointment and metronidazole suppositories, and removal of exposed mesh. Most cases gradually healed in half a year. No mesh exposure progression was detected. There were eight patients who were admitted for removal of exposed mesh and after mesh resection the vaginal mucosa healed completely.

**Comparison of risks factors between the two groups**
Thirty-two patients with mesh exposure were recruited into the exposed group and the other 163 patients were recruited into the nonexposed group.

**Table 1: Demography of patients with MESH exposure (n = 32)**

| Variables                  | Range       | Mean ± SD   | 95% CI         |
|----------------------------|-------------|-------------|----------------|
| Age (years)                | 43.0–81.0   | 64.3 ± 8.8  | 61.1–67.5      |
| Menopausal status (years)  | 0–50.0      | 14.6 ± 9.4  | 11.2–18.0      |
| Gravidity (times)          | 1.0–7.0     | 3.3 ± 1.4   | 2.8–3.8        |
| Parity (times)             | 1.0–6.0     | 2.3 ± 0.2   | 1.8–2.7        |
| BMI (kg/m²)                | 20.0–33.3   | 25.0 ± 2.6  | 24.0–25.9      |
| Exposure time (months)     | 1.0–24.0    | 5.2 ± 4.7   | 3.5–7.0        |
| Diameter (cm)              | 0.3–1.5     | 0.6 ± 0.3   | 0.5–0.7        |
| Operative time (h)         | 1.0–3.0     | 1.6 ± 0.7   | 1.2–1.7        |
| Blood loss (ml)            | 90.0–300.0  | 172.4 ± 75.3| 142.7–216.4    |

BMI: Body mass index; CI: Confidence interval; SD: Standard deviation.
As shown in Table 2, the median age, the operative time, and the blood loss were comparable in the nonexposed and exposed groups. Statistical analysis revealed no significant difference for menopausal status, gravidity and parity, BMI, blood loss, age, or postoperative morbidity. However, the number of concomitant procedures in the nonexposed group was significantly lower than those in the exposed group. The postoperative morbidity in the two groups was 2% and 3%, respectively. The difference was not significant.

Logistic regression analysis of the risk factors for mesh exposure

Logistic regression analysis of the risk factors for mesh exposure was performed in 195 patients [Table 3]. Risk factors for mesh exposure in our analysis included operative duration and the concomitant procedures ($P = 0.043$, $P = 0.001$). The relative risk was 1.899 and 0.376, respectively, for operative time and number of operations. Other factors such as age, menopausal status, gravidity, parity, BMI, and blood loss were not related to mesh exposure.

**DISCUSSION**

**Mesh exposure rate after RPS with transvaginal mesh**

Epidemiological studies have shown that 29.2% of the POP patients need to be reoperated after traditional operation, especially in advanced POP. Some patients may even need several operations.[13] The synthetic PP mesh has been used more widely in pelvic reconstructive surgery for the past 10–20 years. However, the related complications of PP mesh have been reported occasionally and some of them are serious and life-threatening. Mesh exposure was most often seen in PP mesh-related complications. Its occurrence varies significantly among different studies. In 2007, Falagas reported that the incidence of mesh exposure rate ranged from 0% to 33%.[8] PP mesh erosion was reported in 20% of the patients by Defieux et al., 11.3% by Caquant from France, and 20% by Antoine Béclère Hospital.[9–11] Recently,
In our study, mesh exposure increased, possibly due to a longer operative time. In this study, we used 3 different types of meshes. The subsequent regression analysis has also not revealed any significant difference. There are several possible reasons age was not a factor in our study. First, we tried to reserve the vaginal mucosa as much as possible during our operation. Second, we used estrogen ointment locally before and after the operation. Third, our sample may not be large enough to reveal a difference.

**Operation type, concomitant procedure, and mesh exposure**

The number of concomitant operation procedures is another contributing factor for mesh exposure. In 2004, Thompson *et al.* reported abdominosacral fixation combined with total hysterectomy led to higher rate of mesh exposure. *Collinet et al.* believed that risk factors for mesh exposure were concomitant hysterectomy and inverted T colpotomy while Ganj *et al.* thought the most important factor was the length of the incisions in vagina mucosa and the tension on the incision line. Controversially, Stepanian *et al.* found that concomitant hysterectomy would not increase the risk of mesh exposure. In our experience, inverted T colpotomy is more invasive. Exposure was significantly higher in patients who received posterior vaginal wall colporrhaphy, perineorrhaphy, and vaginal tape. Binary logistic regression analysis showed that the number of concomitant procedures and operative time were risk factors for mesh exposure. As the number of concomitant procedures increased, the rate of mesh exposure increased, possibly due to a longer operative time. In this study, we used 3 different types of meshes. Prolift usually is placed as a whole sheet without adjusting. It can be stretched evenly with puncture needle going through the skin. Prosima was smaller and can be adjusted by clipping but is not as evenly placed as Prolift. Ventricular septal defect is maintained for 28 days after Prosima placement, which may arouse a local inflammation reaction. It is placed in vaginal wall without puncture needle guidance. Our results showed that Prosima, Prolift, and Mesh had an exposure rate of 19.1%, 15.9%, and 12.3%, respectively. Although Prosima showed a higher exposure occurrence, statistical analysis did not reveal any difference among them, indicating they share similar exposure hazards.

It was reported that surgeon’s experience is also related with mesh exposure. In our hospital, the rate of mesh exposure was 14.6% in the first 5 years and 17% in the following 3 years. The surgeons did not change during these years. This indicated that the surgeon’s experience might not be a strong protective factor for mesh exposure. In addition, it was found that the exposure rate of vaginal tape was only 1.6%, which indicated vaginal tape was safer and less likely to have mesh exposure. The warning from US FDA regarding TVM indicates improper use of mesh may cause serious safety problems. Thus, close follow-up needs to be performed after the operation. The surgeons’ professional skills should be strengthened to reduce the incidence of complications. Candidates should be carefully chosen, usually patients with advanced POP. Furthermore, alternative nonsurgical treatment or autologous tissue reconstructive surgery should be explored. Access system should be implemented to select eligible surgeons, and a standardized management system should be established for pelvic surgery.

In general, our results showed that TVM surgery is beneficial for patients with advanced POP. Although exposure may occur after surgery, exposure rate was low and easy to manage. At the same time, patients should be cautiously evaluated before mesh surgery.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Subak LL, Waetjen LE, van den Eeden S, Thom DH, Vittinghoff E, Brown JS. Cost of pelvic organ prolapse surgery in the United States. Obstet Gynecol 2001;98:646‑51. doi: 10.1016/S0029‑7844(01)01472‑7.
2. Sand PK, Koduri S, Lobel RW, Winkler HA, Tomeszko J, Culligan PJ, et al. Prospective randomized trial of polyglactin 910 mesh to prevent recurrence of cystoceles and rectoceles. Am J Obstet Gynecol 2001;184:1357‑62. doi: 10.1067/mob.2001.115118.
3. Boreham MK, Wai CY, Miller RT, Schaffer JJ, Word RA. Morphometric analysis of smooth muscle in the anterior vaginal wall of women with pelvic organ prolapse. Am J Obstet Gynecol 2002;187:56‑63. doi: 10.1067/mob.2002.124843.
4. Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL. Epidemiology of surgically managed pelvic organ prolapse and...
urinary incontinence. Obstet Gynecol 1997;89:501-6. doi: 10.1016/S0029-7844(97)00058-6.
5. Stanford E, Moen M. Patient safety communication from the Food and Drug Administration regarding transvaginal mesh for pelvic organ prolapse surgery. J Minim Invasive Gynecol 2011;18:689-91. doi: 10.1016/j.jmig.2011.09.004.
6. Haylen BT, Freeman RM, Swift SE, Barber MD, Camargo S, Dandolu V, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) & grafts in female pelvic floor surgery. Int Urogynecol J 2011;22:3-15. doi: 10.1007/s00192-011-1346-8.
7. Muffly MD, Barber MD. Insertion and removal of vaginal mesh for pelvic organ prolapse. Clin Obstet Gynecol 2010;53:99-114. doi: 10.1097/GRF.0b013e3181c16efab.
8. Falagas ME, Velakoulis S, Iavazzo C, Athanasiou S. Mesh-related infections after pelvic organ prolapse repair surgery. Eur J Obstet Gynecol Reprod Biol 2007;134:147-56. doi: 10.1016/j.ejogrb.2007.02.024.
9. Defleux X, de Tayrac R, Huel C, Bottero J, Gervaise A, Bonnet K, et al. Vaginal mesh erosion after transvaginal repair of cystocele using Gynemesh or Gynemesh-Soft in 138 women: A comparative study. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:73-9. doi: 10.1007/s00192-005-0041-2.
10. Caquant F, Collinet P, De Grandi P. Bulking agents and their place in the treatment of urinary stress incontinence. Gynakol Geburtshilfliche Rundsch 2006;46:39-44. doi: 10.1159/000089976.
11. de Tayrac R, Picone O, Chauveau-Lambling A, Fernandez H. A 2-year anatomical and functional assessment of transvaginal rectocele repair using a polypropylene mesh. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:100-5. doi: 10.1007/s00192-005-1317-2.
12. Achtari C, Hiscock R, O’Reilly BA, Schierlitz L, Dwyer PL. Risk factors for mesh erosion after transvaginal surgery using polypropylene (Atrium) or composite polypropylene/polylactin 910 (Vypro II) mesh. Int Urogynecol J Pelvic Floor Dysfunct 2005;16:389-94. doi: 10.1007/s00192-004-1272-3.
13. Kaufman Y, Singh SS, Alturki H, Lam A. Age and sexual activity are risk factors for mesh exposure following transvaginal mesh repair. Int Urogynecol J 2011;22:307-13. doi: 10.1007/s00192-010-1270-6.
14. Kim J, Lucioni A, Govier F, Kobashi K. Worse long-term surgical outcomes in elderly patients undergoing SPARC retropubic midurethral sling placement. BJU Int 2011;108:708-12. doi: 10.1111/j.1464-410X.2010.09880.x.
15. Gabriel B, Rubod C, Córdova LG, Lucot JP, Cosson M. Prolapse surgery in women of 80 years and older using the Prolift™ technique. Int Urogynecol J 2010;21:1463-70. doi: 10.1007/s00192-010-1217-y.
16. Ghezzi F, Uccella S, Crami A, Bogani G, Candeloro I, Serati M, et al. Surgical treatment for pelvic floor disorders in women 75 years or older: A single-center experience. Menopause 2011;18:314-8. doi: 10.1097/gme.0b013e3181f2e629.
17. Thompson PK, Pugmire JE, Sangi Haghyeykar H. Abdominal sacrocopexy utilizing Tortex Tx in genital prolapse. Pelvic Med Surg 2004;10:311-7. doi: 10.1097/spv.0000156965.48499.14.
18. Collinet P, Belot F, Debedinamion P, Ha Duc E, Lucot JP, Cosson M. Transvaginal mesh technique for pelvic organ prolapse repair: Mesh exposure management and risk factors. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:315-20. doi: 10.1007/s00192-005-0003-8.
19. Sayasneh A, Johnson H. Risk factors for mesh erosion complicating vaginal reconstructive surgery. J Obstet Gynecol Res 2010;30:721-4. doi: 10.3109/01443615.2010.501921.
20. Gaj F, Ibeanu OA, Bedestani A, Nolan TE, Chesson RR. Complications of transvaginal monofilament polypropylene mesh in pelvic organ prolapse repair. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:919-25. doi: 10.1007/s00192-009-0879-9.
21. Stepanian AA, Miklos JR, Moore RD, Mattox TF. Risk of mesh extrusion and other mesh-related complications after laparoscopic sacral colpopexy with or without concurrent laparoscopic-assisted vaginal hysterectomy. Experience of 402 patients. J Minim Invasive Gynecol 2008;15:188-96. doi: 10.1016/j.jmig.2007.11.006.
22. Fatton B, Amblard J, Debedinamion P, Cosson M, Jacquetin B. Transvaginal repair of genital prolapse: Preliminary results of a new tension-free vaginal mesh (Prolift technique) – A case series multicentric study. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:743-52. doi: 10.1007/s00192-006-0234-3.
23. Achtari C, Meyer S, De Grandi P. Bulking agents and their place in the treatment of urinary stress incontinence. Gynakol Geburtshilfliche Rundsch 2006;46:39-44. doi: 10.1159/000089976.
24. Wit Hansen MI, Viervouw ME, Hendriks JC, Kluivers KB, Milani AL. Risk factors for exposure, pain, and dyspareunia after tension-free vaginal mesh procedure. Obstet Gynecol 2011;118:629-36. doi: 10.1097/AOG.0b013e31823835a9.
25. Murphy M, Holzberg A, van Raalte H, Kohli N, Goldman HB, Lucente V; Pelvic Surgeons Network. Time to rethink: An evidence-based response from pelvic surgeons to the FDA Safety Communication: “UPDATE on Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse”. Int Urogynecol J 2012;23:5-9. doi: 10.1007/s00192-011-1581-2.